Reader Responses to GLP-1 Weight Loss Drugs and Insurance Coverage Changes

Readers responded to a February 22 Boston Globe article titled 'The GLP-1 Trap,' which discussed challenges with GLP-1 medications such as Ozempic, Wegovy, Mounjaro, and Zepbound. These drugs, part of the glucagon-like peptide-1 receptor agonist class, are used for weight management and type 2 diabetes.

The responses reflect debates on obesity classification, insurance coverage, and drug affordability.

Several readers affirmed obesity as a recognized disease. Organizations including the Centers for Disease Control and Prevention, American Medical Association, National Institutes of Health, American Academy of Pediatrics, and World Health Organization classify obesity as a chronic disease.

One reader noted that denying coverage for these medications affects individuals who maintain diets and exercise but struggle with weight loss.

A reader with non-alcoholic fatty liver disease, pre-type 2 diabetes, and high blood pressure reported using Mounjaro, which normalized their liver enzymes, A1C levels, and reduced blood pressure.

Another self-pays $449 per month for Zepbound vials and described the ability to afford it as a privilege. These accounts illustrate the drugs' applications for multiple conditions. Obesity rates have increased in the United States and parallel rises have been observed in some laboratory animals on controlled diets with unchanged calorie and nutrient intake.

Researchers are investigating potential environmental factors, changes in food supply, or epigenetic influences across species. This suggests complexity in obesity causes beyond individual choices.

Some readers contested obesity as a disease, comparing it to smoking or gun deaths as outcomes of personal decisions.

They argued against insurance subsidizing the costs, stating individuals should bear the expenses of their choices. The drugs remain expensive, with insurers facing challenges in covering widespread use. Other responses criticized high pharmaceutical prices charged to those in need.

One reader predicted that wealthier individuals would continue accessing the drugs while lower-income people would not, potentially widening health outcome disparities. Versions of the drugs are available at half the price from compounding pharmacies, though their safety and effectiveness require further evaluation.

In some countries, GLP-1 drugs are approaching patent expiration, which could lead to price drops.

In the United States, reduced affordability might prompt pharmaceutical companies to adjust pricing for broader market access. One reader disagreed with an online headline stating 'The GLP-1 dream is over,' asserting that adoption in America is in early stages.